Tags

Type your tag names separated by a space and hit enter

Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
J Psychopharmacol. 2014 Apr; 28(4):341-8.JP

Abstract

This study aimed to investigate changes in plasma concentrations of risperidone and 9-hydroxy-risperidone (9-OHR) and the associated clinical effects when switching from oral risperidone to extended-release (ER) paliperidone in patients with schizophrenia. This study included 25 patients with schizophrenia. Following a one-week screening period with a stable dose of risperidone, a six-week open-label switch study from risperidone to extended-release paliperidone (paliperidone ER) was conducted. Efficacy and safety assessments were performed on Day 1 and at Weeks 1, 2, 4, and 6. Plasma levels of the active fractions of oral risperidone and paliperidone ER were measured on Day 1 and at Week 1, respectively. Plasma levels of the active moiety (risperidone plus 9-OHR) while taking risperidone (mean dose: 4.0 mg) were significantly higher than plasma levels of 9-OHR while taking 6 mg of paliperidone ER. For 12 subjects taking only 3 mg of risperidone, plasma concentrations of the active moiety of risperidone were also significantly higher than those of 9-OHR while taking 6 mg of paliperidone ER. The amount of reduction in plasma levels was correlated with a temporal deterioration of clinical symptoms. These findings suggest that for patients with schizophrenia taking 3 mg or more of risperidone, an initial switching dose of 6 mg of paliperidone ER may be relatively low in terms of subsequent plasma concentrations and the associated clinical response.

Authors+Show Affiliations

1Department of Psychiatry, Kyungpook National University School of Medicine, Daegu, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24346811

Citation

Yang, Dong Suk, et al. "Changes in Plasma Concentrations of Risperidone and 9-hydroxyrisperidone and the Associated Clinical Effects During the Switch From Oral Risperidone to Extended-release Paliperidone Tablets in Patients With Schizophrenia." Journal of Psychopharmacology (Oxford, England), vol. 28, no. 4, 2014, pp. 341-8.
Yang DS, Seong SJ, Yoon YR, et al. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia. J Psychopharmacol. 2014;28(4):341-8.
Yang, D. S., Seong, S. J., Yoon, Y. R., Lim, M. S., Kwak, K. H., & Lee, S. J. (2014). Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia. Journal of Psychopharmacology (Oxford, England), 28(4), 341-8. https://doi.org/10.1177/0269881113516203
Yang DS, et al. Changes in Plasma Concentrations of Risperidone and 9-hydroxyrisperidone and the Associated Clinical Effects During the Switch From Oral Risperidone to Extended-release Paliperidone Tablets in Patients With Schizophrenia. J Psychopharmacol. 2014;28(4):341-8. PubMed PMID: 24346811.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia. AU - Yang,Dong Suk, AU - Seong,Sook Jin, AU - Yoon,Young-Ran, AU - Lim,Mi-Sun, AU - Kwak,Kyung-Hwa, AU - Lee,Seung Jae, Y1 - 2013/12/17/ PY - 2013/12/19/entrez PY - 2013/12/19/pubmed PY - 2014/12/15/medline KW - 9-hydroxy-risperidone KW - Paliperidone KW - risperidone KW - schizophrenia KW - switching dose SP - 341 EP - 8 JF - Journal of psychopharmacology (Oxford, England) JO - J Psychopharmacol VL - 28 IS - 4 N2 - This study aimed to investigate changes in plasma concentrations of risperidone and 9-hydroxy-risperidone (9-OHR) and the associated clinical effects when switching from oral risperidone to extended-release (ER) paliperidone in patients with schizophrenia. This study included 25 patients with schizophrenia. Following a one-week screening period with a stable dose of risperidone, a six-week open-label switch study from risperidone to extended-release paliperidone (paliperidone ER) was conducted. Efficacy and safety assessments were performed on Day 1 and at Weeks 1, 2, 4, and 6. Plasma levels of the active fractions of oral risperidone and paliperidone ER were measured on Day 1 and at Week 1, respectively. Plasma levels of the active moiety (risperidone plus 9-OHR) while taking risperidone (mean dose: 4.0 mg) were significantly higher than plasma levels of 9-OHR while taking 6 mg of paliperidone ER. For 12 subjects taking only 3 mg of risperidone, plasma concentrations of the active moiety of risperidone were also significantly higher than those of 9-OHR while taking 6 mg of paliperidone ER. The amount of reduction in plasma levels was correlated with a temporal deterioration of clinical symptoms. These findings suggest that for patients with schizophrenia taking 3 mg or more of risperidone, an initial switching dose of 6 mg of paliperidone ER may be relatively low in terms of subsequent plasma concentrations and the associated clinical response. SN - 1461-7285 UR - https://www.unboundmedicine.com/medline/citation/24346811/Changes_in_plasma_concentrations_of_risperidone_and_9_hydroxyrisperidone_and_the_associated_clinical_effects_during_the_switch_from_oral_risperidone_to_extended_release_paliperidone_tablets_in_patients_with_schizophrenia_ L2 - https://journals.sagepub.com/doi/10.1177/0269881113516203?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -